Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals is supported by a strengthening commercial base, led by Fanapt’s robust momentum with 1Q26 net product sales of $29.6M, up 26% year-over-year, while total 1Q26 net product sales reached $51.7M and management raised 2026 revenue guidance to $240M-$290M, indicating that newer launches are beginning to offset pressure elsewhere in the portfolio. The bullish case is further reinforced by the expected BYSANTI transition, which is poised to add incremental FY26 revenue and potentially accelerate the FANAPT/BYSANTI line toward materially higher growth in FY27, while NEREUS commercialization adds another near-term revenue stream and the company ended 1Q26 with $202.3M in cash and marketable securities. Despite HETLIOZ facing generic erosion and ongoing litigation costs, the outlook remains constructive because Vanda retains multiple late-stage and commercial catalysts, including THETIS by YE26, a 2026 legal and regulatory event calendar, and a path toward improving profitability as Fanapt growth, new product contributions, and lower relative SG&A drag increasingly support the earnings trajectory.

Vanda Pharmaceuticals is facing a fundamentally weaker earnings and revenue profile, as 2Q26 net product sales of $50.5M missed expectations despite a roughly $7.0M HETLIOZ shipment timing benefit that will only be recognized in 3Q26, while the company’s 2Q26 loss before income taxes widened to $62.4M from $34.9M a year ago. The commercial mix remains fragile because Fanapt contributed $36M of 2Q26 sales but HETLIOZ fell 66% year over year to $5.6M, PONVORY grew only modestly to $7.9M, and tradipitant still generated just $1M even after its U.S. launch in May 2026, leaving the company dependent on a narrow set of products and vulnerable to slower-than-expected traction, generic erosion, and pricing pressure. Although cash, cash equivalents, and marketable securities totaled $170M at the midpoint of 2026 and management said resources should fund operations at least through next year, the need for continued R&D and launch investment, alongside regulatory, clinical, and IP risks and the possibility of medium-term dilution, supports a negative outlook despite the maintained full-year 2026 revenue guidance range of $240-290M.